Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by fredgoodwinsonon Oct 27, 2020 3:48am
159 Views
Post# 31786691

RE:RE:At last a schedule

RE:RE:At last a schedule

Thanks for your reply.

 

The million dollar question is whether they can treat GBM - and maybe even NSCLC - with Rutherrin and X-ray only? Roswell Park are limited to TLD-1433 which cannot be activated exogenously so they have to use their OSA plus Digilum. If TLT can make these compounds work non-invasively then things should hot up very quickly next year. A substantial partial response was observed preclinically with X-Ray at levels 27-fold less the those used in historic attempts to destroy GBM so there is probably good leeway to increase the light dose from there.

Yes G1 timelines have slipped time and again but they have been experimenting with Rutherrin for over 5 years now. It is a known quantity to them in terms of toxicity which represents the greatest majority of the remaining preclinical work. 

Bullboard Posts